Taeho Greg Rhee1, Robert A Rosenheck2. 1. Department of Community Medicine and Health Care, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States; Veterans Affairs (VA) New England Mental Illness Research, Education and Clinical Centers (MIRECC), West Haven, CT, United States; Veterans Affairs (VA) Connecticut Healthcare System, West Haven, CT, United States. Electronic address: tgrhee.research@gmail.com. 2. Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States; Veterans Affairs (VA) New England Mental Illness Research, Education and Clinical Centers (MIRECC), West Haven, CT, United States; Veterans Affairs (VA) Connecticut Healthcare System, West Haven, CT, United States.
Abstract
OBJECTIVES: Both psychiatric polypharmacy and multimorbidity are common in depressed adults. We examine recent patterns of psychotropic polypharmacy with attention to concurrent multimorbidity in the treatment of depressive disorders in outpatient psychiatric care. METHODS: Data from the 2006-2015 National Ambulatory Medical Care Survey offer nationally representative samples of office-based psychiatric care in adults with depressive disorders (ICD-9-CM codes 296.20-296.26, 296.30-296.36, 300.4, 311, and 301.10-301.13) (n = 6,685 unweighted). These data allowed estimation of the prevalence of polypharmacy (within-class, between-class, and both) involving four major psychotropic classes: antidepressants, antipsychotics, mood-stabilizers, and sedative-hypnotics. We further evaluated the proportion of within-class and between-class psychotropic prescription combinations that were potentially justifiable, taking FDA-approved indications and multimorbidity into consideration. RESULTS: Prescribing two or more psychotropic medications for depressed adults remained substantial and stable ranging from 59.0% in 2006-2007 to 58.0% in 2014-2015. The most common within-class polypharmacy types were: antidepressants (22.7%) and sedative-hypnotics (14.8%). The most common between-class polypharmacy types were: an antidepressant and a sedative-hypnotic (30.7%), an antidepressant and an antipsychotic (16.4%), and an antipsychotic and a sedative-hypnotic (9.0%). In visits in which between-class psychotropics were prescribed, 53.9% were potentially justified by FDA-approved augmentation and/or adjunctive treatment strategies or by psychiatric multimorbidities. CONCLUSION: Psychotropic polypharmacy affects more than half of depressed adults. Between-class polypharmacy is the most common pattern and in over 50% of instances may be justified by augmentation strategies or considerations of psychiatric multimorbidity. Future research is needed to address effectiveness, safety, and cost-effectiveness of polypharmaceutical care for depression, especially those occurring with psychiatric co-morbididities.
OBJECTIVES: Both psychiatric polypharmacy and multimorbidity are common in depressed adults. We examine recent patterns of psychotropic polypharmacy with attention to concurrent multimorbidity in the treatment of depressive disorders in outpatientpsychiatric care. METHODS: Data from the 2006-2015 National Ambulatory Medical Care Survey offer nationally representative samples of office-based psychiatric care in adults with depressive disorders (ICD-9-CM codes 296.20-296.26, 296.30-296.36, 300.4, 311, and 301.10-301.13) (n = 6,685 unweighted). These data allowed estimation of the prevalence of polypharmacy (within-class, between-class, and both) involving four major psychotropic classes: antidepressants, antipsychotics, mood-stabilizers, and sedative-hypnotics. We further evaluated the proportion of within-class and between-class psychotropic prescription combinations that were potentially justifiable, taking FDA-approved indications and multimorbidity into consideration. RESULTS: Prescribing two or more psychotropic medications for depressed adults remained substantial and stable ranging from 59.0% in 2006-2007 to 58.0% in 2014-2015. The most common within-class polypharmacy types were: antidepressants (22.7%) and sedative-hypnotics (14.8%). The most common between-class polypharmacy types were: an antidepressant and a sedative-hypnotic (30.7%), an antidepressant and an antipsychotic (16.4%), and an antipsychotic and a sedative-hypnotic (9.0%). In visits in which between-class psychotropics were prescribed, 53.9% were potentially justified by FDA-approved augmentation and/or adjunctive treatment strategies or by psychiatric multimorbidities. CONCLUSION: Psychotropic polypharmacy affects more than half of depressed adults. Between-class polypharmacy is the most common pattern and in over 50% of instances may be justified by augmentation strategies or considerations of psychiatric multimorbidity. Future research is needed to address effectiveness, safety, and cost-effectiveness of polypharmaceutical care for depression, especially those occurring with psychiatric co-morbididities.
Authors: Somaia Mohamed; Gary R Johnson; Julia E Vertrees; Peter D Guarino; Kimberly Weingart; Ilanit Tal Young; Jean Yoon; Theresa C Gleason; Katherine A Kirkwood; Amy M Kilbourne; Martha Gerrity; Stephen Marder; Kousick Biswas; Paul Hicks; Lori L Davis; Peijun Chen; AlexandraMary Kelada; Grant D Huang; David D Lawrence; Mary LeGwin; Sidney Zisook Journal: Psychiatry Res Date: 2015-08-06 Impact factor: 3.222
Authors: Jessica L Gören; Joseph J Parks; Frank A Ghinassi; Celeste G Milton; John M Oldham; Pablo Hernandez; Jeffrey Chan; Richard C Hermann Journal: Jt Comm J Qual Patient Saf Date: 2008-10
Authors: H-J Möller; F Seemüller; R Schennach-Wolff; S Stübner; E Rüther; R Grohmann Journal: Int J Neuropsychopharmacol Date: 2013-09-18 Impact factor: 5.176
Authors: Gerardo Villarreal; Mark B Hamner; José M Cañive; Sophie Robert; Lawrence A Calais; Valerie Durklaski; Yusheng Zhai; Clifford Qualls Journal: Am J Psychiatry Date: 2016-07-15 Impact factor: 18.112
Authors: H H Stassen; S Bachmann; R Bridler; K Cattapan; D Herzig; A Schneeberger; E Seifritz Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-11-25 Impact factor: 5.760
Authors: Rebecca Mellor; Andrew Khoo; Elise Saunders-Dow; Ella Raguz; Meng-Wong Taing; Leila Shafiee Hanjani; Chris Freeman; Darrell Crawford Journal: Drugs Real World Outcomes Date: 2022-05-17
Authors: H H Stassen; S Bachmann; R Bridler; K Cattapan; D Herzig; A Schneeberger; E Seifritz Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-07-21 Impact factor: 5.270